<DOC>
	<DOCNO>NCT01858883</DOCNO>
	<brief_summary>Test hypothesis INCB039110 administer safely combination gemcitabine nab-paclitaxel subject advance metastatic cancer .</brief_summary>
	<brief_title>Safety Study INCB039110 Combination With Gemcitabine Nab-Paclitaxel Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>Study Part 1 : This dose optimization phase design find tolerated regimen include identify MTD INCB039110 ( within define pharmacologic range ) combination dose gemcitabine nab-paclitaxel establish safety tolerability subject advance metastatic solid tumor . Study Part 2 Part 2A : This phase explore safety tolerability MTD PAD INCB039110 administer combination gemcitabine nab-paclitaxel subject untreated advance metastatic pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically cytologically confirm solid tumor ( Part 1 ) pancreatic adenocarcinoma ( Part 2 ) Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Received 1 prior chemotherapy regimen advance metastatic disease ( include neoadjuvant and/or adjuvant therapy ) ( Part 1 ) Received prior chemotherapy advance metastatic disease ( Part 2 Part 2a ) Adequate renal , hepatic , bone marrow function without frequent blood product hematopoietic growth factor support ( eg use erythropoietin transfusion &gt; 2 unit pack red blood cell every 3 month ) Ability swallow retain oral medication Any known contraindication use require comedication ( gemcitabine nabpaclitaxel ) . Evidence uncontrolled brain metastasis history uncontrolled seizure . Ongoing radiation therapy and/or radiation therapy administer within 28 day enrollment ongoing radiotherapyrelated toxicity . Presence ≥ Grade 2 neuropathy . Inability swallow food condition upper GI tract precludes administration oral medication . Recent ( ≤ 3 month ) history partial complete bowel obstruction . Unwillingness transfuse blood component . Known history Hepatitis B C infection HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>